We describe five new mutations in the uroporphyrinogen decarboxylase (UROD) gene. All mutations were observed in conjunction with decreased erythrocyte UROD and clinical familial porphyria cutanea tarda (fPCT), (four families) or hepatoerythropoietic porphyria (HEP), (one family). The fPCT mutations included three point mutations that resulted in amino acid substitutions: a lysine t o glutamine at amino acid position 253 (exon 7); a glycine t o arginine at position 318 (exon 10); an isoleucine t o threonine at position 334 (exon 10). The lysine t o glutamine at amino acid position 253 was found in conjunction with a single C nucleotide deletion in exon 8 on the same allele of the UROD gene in the same family. This deletion resulted in a shift in the reading frame and the introduction of a premature stop codon 8 amino acids downstream. In the fourth family, a 31-bp deletion (nucleotides 828-858: exon 8) of the coding region, resulted HE PRODUCTION of hemoglobin depends on both the T regulated synthesis of globin'.' and the coordinated production of heme.' The regulation of heme synthesis occurs via a biosynthetic pathway that involves multiple enzymes. The importance of the heme biosynthetic pathway is evidenced by the conservation of these enzymes through millions of years of evolution. Defects in these enzymes can result in several dramatic clinical syndromes, collectively called the porphyrias: The most common of these, porphyria cutanea tarda5 (PCT) is associated with skin photosensitivity and blistering in sun exposed areas, which may result in scarring. Other cutaneous symptoms include sclerodermoid changes, skin fragility, and hypertrich~sis.~ There. is a familial form of PCT that represents about 20% of all P C P whereas much less common is hepatoerythropoietic porphyria7 (HEP), which is clinically similar but more severe than PCT.4 Both these diseases are caused by defects in the enzyme uroporphyrinogen decarboxylase (UROD). As a consequence, UROD activity is reduced to approximately 50% of normal in PCT*-'' and between 5% and 30% in HEP. I '
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The human UROD gene codes for the fifth enzyme in the heme biosynthetic pathway. This enzyme is responsible for the stepwise decarboxylation of uroporphyrinogen I11 (an eight carboxylic acid porphyrinogen), through to coproporphyrinogen I11 (a four carboxylic acid porphyrinogen). 12-14 The number of catalytic site(s) where decarboxylation takes place are not known. The UROD cDNA has been cloned and ~equenced'~,'~ and the gene assigned to p34 on chromosome i. I7 Several genetic abnormalities have been described in the UROD gene in HEP. In contrast, two abnormalities have been described in familial PCT (fPCT). In HEP, point mutations have been observed in exons 5," 6," 7," and 8.'9.20 In addition, a large deletion has been characterized?' Some of these mutations have been observed in more than one family. The two mutations that have been described for the UROD gene in PCT include the substitution of glycine by valine at amino acid position 28 1 21 and a splicing error, which results in a UROD mRNA transcript that lacks exon 6?2 The splice in a framesh)t and the introduction of a stop codon 19 amino acids downstream. A point mutation was observed in an individual diagnosed with HEP, resulting in an alanine t o glycine change at amino acid position 80 and was present on both alleles. All mutations were confirmed in at least one other family member. The impact of these mutations on the function of the UROD protein was examined using in vitro protein expression and with activity assessed using pentacarboxylic acid porphyrinogen I as a substrate for UROD. Although three mutations reduced UROD activity t o <15% of normal, one resulted in a UROD protein with 50% functional activity and the other had near normal activity. These results indicate that many different genetic lesions of the UROD gene are associated with fPCT.
0 1996 by The American Society of Hemato/ogy. junction error was detected in 5 of 22 apparently unrelated families with P C T but no defect in the UROD gene was defined in several other families that were examined."
We have cloned and sequenced the UROD cDNA using polymerase chain reaction (PCR) amplification and identified five new mutations in unrelated families with WCT and one family with HEP. All mutations differ from those previously reported. The proteins encoded by these mRNAs were translated in vitro and demonstrated with the exception of one mutant to have reduced activity compared with the normal UROD protein.
MATERIALS AND METHODS

Erythrocyte UROD Activity Measurement
Erythrocyte UROD was measured by one of two methods. In method I , whole blood was incubated with pentacarboxylic acid porphyrinogen 1 (pentacarboxylic acid porphyrin I; Porphyrin Products, Logan, UT) at 37°C for 30 minutes in a phosphate buffer at pH 6.0. The reaction was terminated with a mixture of 0.61 mmoll L trichloroacetic acid and dimethyl sulfoxide in equal volumes containing mesoporphyrin (Porphyrin Products) as an internal standard. The coproporphyrin product was separated from the substrate by high performance liquid chromatography, detected by fluorescence and compared with a coproporphyrin 111 (Porphyrin Products) standard."
The UROD activity in some individuals was measured by a modified method of Alleman et al,z4 method 2. Porphobilinogen (Porphyrin Products) was incubated with erythrocytes at 37°C for 30 minutes in a Tris buffer at pH 8.0. The reaction was terminated with 2.7 m o m HCI containing mesoporphyrin (Porphyrin Products) as an internal standard. The coproporphyrin 111 product was detected as described above.
UROD Immunoreactivity
UROD immunoreactivity was determined by rocket immunoelectrophoresis." A 1% agarose gel in barbital buffer (1.35 g/L barbitone, 7.73 g/L sodium barbital), pH 8.4, containing antihuman UROD antisera was poured using Gelhond film (Extech Equipment. FMC Bioproducts, ME), with dimensions of 85 X 100 mm. A strip of gel 1.5 cm wide along the end, which was to become the origin was removed and replaced with 1% agarose in the same barbital buffer, without antihuman UROD antisera.26 Five microliters of whole blood from each patient plus 5 yL of whole blood from a healthy laboratory worker, applied undiluted and diluted twofold or fourfold, was electrophoresed at between 10 and 15 mA ovemight in barbital buffer (2.7 g/L barbitone, 15.45 g/L sodium barbital), pH 8.4, at 4°C. Following electrophoresis, the gel@) were washed in saline for between 8 and 16 hours with 2 to 3 changes of saline. Gel(s) were then squashed overnight under absorbent paper and a I-kg weight. The next day gels were dried off completely on a 37°C heating block before staining in Coomassie Brilliant Blue R (Bio-Rad, Richmond, CA) and destaining in a mixture of water, methanol, and glacial acetic acid (5:4:1), Peak heights were measured from the origin and a standard curve derived from dilutions of the normal control. Porphyria patient erythrocyte UROD levels were read from the standard curve. The immunoreactive UROD of the single normal control was also one of four normal samples assessed by a modified method of Chin and Sassa" and found to be 9.4 pg UROD/mL packed red blood cells. The mean of the four samples was 8.213 t the standard error of 0.482 yg UROD/mL packed red blood cells.
Isolation of mRNA, cDNA Synthesis, and Extraction of
Genomic DNA
Whole blood was centrifuged and the buffy coat washed in 8 g/L ammonium chloride for 15 minutes at 37°C. Acid guanidinium thiocyanate (International Biotechnologies, New Haven, CT) was used to extract total RNA from leukocytes.28 cDNA synthesis was achieved using avian myeloblastosis virus reverse transcriptase according to the manufacturer's instructions (Boehringer Mannheim, Mannheim, Germany) from a minimum of 25 pg total RNA. Genomic DNA was extracted from 10 mL of peripheral blood either by the method of Sambrook et aIz9 or using a Progenome kit (Progen, Darra, Australia) according to the manufacturer's instructions PCR AmpliBcation of DNA Two approaches were adopted to amplify the cDNA: (1) A fulllength cDNA was generated using two rounds of PCR.3a The first round used oligonucleotides BM2 and BMI (Table 1) as the 5' and 3' primers and oligonucleotides N1 and N4 for the second round (Table 1) . Ten percent of PCR products generated from the first round were used for round two. For round 1 the conditions were: 94°C for 2 minutes, 55°C for 2 minutes, and 72°C for 2 minutes. In the second round of amplification, the annealing temperature was 50°C. (2) The UROD cDNA was amplified in two halves with two primer pairs. Then a second round of the PCR was performed using nested primers. Ten percent of first round PCR product was used in the second round of PCR. For nucleotides 1 through 590, the oligonucleotide primers for the first round were BM2 and BM4 (Table I ) , respectively. The internal oligonucleotide primers for the second round of PCR amplification, were NI and N2 (Table 1) . The result was a 553-bp PCR product. To amplify nucleotides 472-1173 of the UROD cDNA for the first round of PCR, oligonucleotides BM3 and BMI (Table I ) were used. The nested primers for this sequence were N3 and N4 (Table 1 ). This amplification resulted in a product of 661 bp. The first round was 40 cycles: 2 minutes at 94°C. 2 minutes at 55°C. and 2 minutes at 72°C. The second round used an annealing temperature of 50°C. Two minutes at 72°C was deliberately chosen for the elongation time because Taq polymerase can extend at a rate of 1,000 bases per minute.3' When a limited volume of blood was available, genomic DNA was extracted and each exon of the UROD gene amplified using PCR and the primer pairs shown in Table 2 . Each of 40 cycles was 1 minute at 9 5 T , I minute at SST, and 2 minutes at 72°C for all primer pairs. A negative control was included in every PCR experiment. This contained the same PCR reaction mixture but without cDNA or genomic DNA and was shown to be negative on hybridization with radiolabeled UROD cDNA.
All PCR amplification was performed in a Hybaid Thermal Reactor (Teddington, UK) using thermostable polymerase enzyme (Taq polymerase; Promega, Madison, WI).
Electrophoresis of the PCR products was performed in a 1.5% agarose gel. Throughout this report the nucleotide numbering system used for the UROD cDNA is as described by Romeo et al.Is
Labeling of Probes and Hybridization PCR products were transferred to a nylon membrane by the method of Southern, following electrophoresis. The membrane was hybridized with a "P-labeled ("P-ATP from Bresatec, Adelaide, Australia) full-length UROD cDNA probe (a gift from Prof Hubert de Vemeuil from the University of Bordeaux, France), which was labeled using either the random hexamer priming methodz9 (random hexamers from Pharmacia, Uppsala, Sweden) or a Bresatec Gigaprime kit (Bresatec) according to the manufacturer's instructions. Hybridization was performed at 65°C in I mmol/L sodium chloride, I g/L sodium dodecyl sulfate (SDS) and 100 g L dextran sulfate An 18-bp oligonucleotide probe, 8DEL, 5'-GCCCTGGAGGGC-TTGACT-3', which spans the exon 8 deletion (see Results), was synthesized. 8DEL was end labeled with gamma "P-ATP (Bresatec). A NAP-5 column containing Sephadex (3-25 medium (Pharmacia) was used to remove the free "P-ATP. The hybridization was performed at 52°C. The membrane was washed three times in 5 X SSC and 1 g/L SDS for 15 minutes each, followed by one wash in 2 X SSC and 1 g/L SDS, all at room temperature."
Cloning and Sequencing of PCR Products
PCR products, positive on hybridization with radiolabeled UROD cDNA, were electrophoresed in low melting point agarose (USB Corp, Cleveland, OH or Progen). The band(s) of interest were excised from the agarose gel and the amplified DNA extracted by Wizard Preps (Promega) according to the manufacturer's instructions. The purified PCR products were then subjected to nucleotide sequence determination of the entire PCR product. Altematively, they were treated with For personal use only. on November 11, 2017. by guest www.bloodjournal.org From Throughout this report the nucleotide numbering system used for the UROD cDNA is as described by Romeo et aI.l5 Abbreviations: T, , annealing temperature YC); size, predicted size (bp) of PCR product using primer pairs shown; s, sense orientation; UTR, untranslated region: a, antisense orientation.
Klenow and ligated into S m I digested pBluescript (Stratagene, La Jolla, CA). At least five (four for the proband in family 5 [AI]) independent plasmid clones were characterized by sequencing using a modified version of the Sanger dideoxy method3* with T7 DNA polymerase (Pharmacia) or Sequenase (USB).
Screening of Family Members for Relevant Mutations
To confirm mutations within an individual or in other family members, the implicated exon was amplified from genomic DNA using the appropriate primer pairs (see Table 2 ) and sequenced and/ or digested with an appropriate restriction enzyme as follows: To confirm the T to C mutation at nucleotide position 1019 in family 1 (KD), exon 10 was PCR amplified using oligonucleotides 519 and BMl ( Table 2) . subcloned and the nucleotide sequence determined. PCR products were also digested with BsrDl for 2 hours at 65°C and electrophoresed in a 4% acrylamide gel.
To screen for the exon 8 deletion, genomic DNA was amplified using oligonucleotides E7 and Ep9 (Table 2 ) in members of family 2 (CJ). The nucleotide sequence of the PCR products was determined and/or they were electrophoresed in an 8% acrylamide gel, and transferred to a nylon membrane by electroblotting according to the manufacturer's instructions for the Bio-Rad mini protean system. The membrane was then hybridized sequentially with an oligonucleotide probe, which spanned the exon 8 deletion, and radiolabeled UROD cDNA.
The T to A point mutation at nucleotide position 776 in family 3 (MB) was confirmed by amplifying genomic DNA using 516 and Ep9 ( Table 2 ) and subsequent determination of the nucleotide sequence of the PCR products without prior subcloning. The C deletion at nucleotide position 890 was confirmed in the proband's daughter by nucleotide sequencing of four full-lengtb cDNA clones.
To confirm the point mutation at nucleotide position 970 in other Abbreviations: T, , annealing temperature ("C); size, predicted size (bp) of PCR product using primer pairs shown; s, sense orientation; UTR, untranslated region; a, antisense orientation; ex, exon.
For personal use only. on November 11, 2017. by guest www.bloodjournal.org From members of family 4 (MR), genomic DNA was amplified using primers 519 (Table 2) and E10 (5'-GATCAAGCTTGGTCCAAA-GTCATCCAGCAT-3') located in the antisense direction in exon 10 (nucleotides 988-1007). PCR products (266 bp) were Klenow treated and subcloned and the nucleotide sequence determined.
To confirm the C to G substitution at nucleotide position 257 in family 5 (AI), exon 4 was amplified using the primers Ep3 and E5 (Table 2) . For the proband, the PCR products were subjected to nucleotide sequencing (without prior subcloning) whereas those of the father and brother were subcloned into pBluescript before sequencing.
UROD Expression Vector Constructs
To derive full-length cDNA clones, a cross-over PCR strategy was employed using the thermostable polymerase enzyme, pfu (Stratagene) and primer pairs N1 and N4 ( Table 1) . PCR conditions were 40 cycles, each consisting of 1 minute at 9 5 T , 1 minute at 55"C, and 2 minutes at 72°C. PCR products were initially purified by Wizard preps (Promega) after electrophoresis in low melting point agarose gel (USB or Progen), treated with Klenow (Promega), again purified using Wizard preps (Progen) and then ligated into the pMAL-p2 vector (NEB, Beverly, MA) digested with Xmn I. This resulted in the UROD cDNA inserted downstream from the gene for the maltose binding protein (MBP). Either XL1 blue (Stratagene) or NM522 bacteria were transformed with the ligation reactions or the pMAL-p2 vector alone and plated on LB agar plates containing ampicillin (50 pg/mL; Boehringer Mannheim). Colonies were screened by hybridization of nitrocellulose filters with radiolabeled UROD cDNA. Positive clones were grown overnight in 5 mL cultures and the plasmid DNA isolated. Digestion with BamHI was used to determine the orientation of the inserted fragment and the nucleotide sequence confirmed. Bacterial cultures were grown and MBP fusion proteins isolated according to the manufacturer's instructions. Aliquots of partially purified proteins were stored at -70°C. The fusion proteins and factor Xa cleaved proteins were analyzed by Western blot against both anti-MBP (NEB) and anti-UROD antisera. The UROD activity of the MBP fusion proteins and the factor Xa cleaved proteins was determined by method 1 (above).
Analysis of Crude Bacterial Extracts
Eighty milliliter cultures transformed with the pMAL-p2 vector alone, the expression vector containing the normal UROD cDNA, and the mutant cDNA were grown and induced with 0.1 pmol/L isopropyl-P-D-thiogalactoside. The cells were procured and sonicated. Following centrifugation, an aliquot of each supernatant was incubated with factor Xa at 4°C. In addition, the cellular debris was disrupted and vortexed in 1% Triton-X 100 (Calbiochem, La Jolla, CA) in column buffer (prepared according to the manufacturer's instructions for the pMAL-p2 protein expression system, NEB). Both supernatants (with and without factor Xa cleavage) and suspended cellular material were analyzed by Western blot using anti-UROD and anti-MBP antisera. The UROD activity was measured on the factor Xa cleaved supernatants using method I .
Western Analysis
In vitro translated proteins were electrophoresed in an SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and electroblotted onto a nylon membrane (Hybond C; Amersham, Castle Hill, Australia) using the Bio-Rad mini protean system. Western analysis was performed using a Bio-Rad Immunblot kit containing goat antirabbit antisera to detect the rabbit antihuman UROD antisera.
In Vitro Transcription, Translation, and Degradation
The normal UROD cDNA and the UROD cDNA derived from family 4 (MR) were cloned into Sac VEcoRI digested pBluescript vector (Stratagene). "S-labeled UROD proteins were synthesized using "S-labeled methionine (Amersham) and the TNT coupled reticulocyte lysate system and T3 polymerase (Promega) according to the manufacturer's instructions. Five microliters of translation products were exposed to 20 pL (88 pg protein) of' a lymphocyte lysate derived from a normal individual at 37°C. Sample5 were removed at intervals between 0 and 48 hours and analyzed by SDS-PAGE, followed by exposure to x-ray film. Densitometry was used to determine the relative amounts of ?-labeled UROD protein present.
RESULTS
UROD Activity and I~m~?~~~r e a c~i v i~
The diagnosis of PCT was made in the probands of family 1 (KD), family 2 (CJ), family 3 (MB), and family 4 (MR) based on the typical skin photosensitivity associated with PCT, characteristic porphyrin excretion patterns in urine and feces, plasma porphyrin levels, and decreased erythrocyte UROD activity (Table 3) . Urinary, fecal, and plasma porphyrin levels were elevated and isocoproporphyrin was detected in the feces (data not shown). The index patient with HEP (family 5 [AI]) was the daughter of first cousins. The diagnosis of HEP was established clinically based on hirsutism and skin lesions. Biochemically there was decreased erythrocyte UROD (12% of normal, Table 3 ), increased urinary and fecal porphyrin levels including isocoproporphyrin in the feces and increased plasma and erythrocyte protoporphyrin levels (data not shown). The UROD activity of 12% is consistent with other reports of UROD activity in this severe homozygous cutaneous porphyria.' ' As shown in Table 3 , low UROD activity (reduced to approximately 50% of normal) was shown in each proband and at least one other family member although some of these individuals had no symptoms of PCT. Of the proband AI'S relatives (diagnosis HEP), only the father and brother were available for testing. In both relatives, although there was no clinical evidence of porphyria, the erythrocyte UROD was reduced to about 50% of normal suggesting that they may have been heterozygous carriers.
Immunoreactive UROD protein (Table 3) , was also determined, using immunoelectrophoresis. Results were calculated as a percentage of a normal control, assigned a value of loo%, which had a concentration of 9.4 pg UROD/mL packed red blood cells by a quantitative method.27 Most fPCT patients had an estimated immunoreactive UROD protein concentration between 30% and 44% of normal. In general, this correlated well with the estimate of UROD based on functional assays and suggested the absence of immunoreactive, but functionally inactive, UROD protein in these families. However, in family 5 (AI), the difference between biological activity (12%) and immunoreactivity (28%) may reflect the presence of some biologically inactive but immunoreactive protein. This discordance between the UROD immunoreactivity and functional activity may also be partly due to the use of a single healthy laboratory worker as the normal control, the difficulty in accurately quantitating immunoreactivity and the variability from assay to assay.*' The father of the proband in family 5 (AI) had an estimated UROD concentration of 62%, again supporting likely heterozygosity in the proband's father.
Mutations in the UROD Gene
Family I (KD). In the proband of family 1 (KD), each exon was amplified. Nucleotide sequencing of the entire PCR amplified (nonsubcloned) product revealed both a T and C nucleotide at position 1019 (Fig lA) , confirming the presence of both normal and mutated alleles. The substitution of C for T at this position of the coding region would result in the substitution of isoleucine for threonine at amino acid position 334 (Table 4) . Determination of the exon 10 sequence in the proband's parents revealed the same nucleotide substitution in DNA from the mother, whereas the exon 10 sequence in the father was normal (data not shown). This nucleotide alteration predicted the loss of a BsrDI site. The absence of this site was then documented, thus confirming this point mutation in the genomic DNA of both the proband and her mother (Fig 2D) .
The nucleotide sequence of 11 clones comprising the two halves of the UROD cDNA were characterized from family 2 (CJ). In three clones (derived from the 3' half of the UROD cDNA), a deletion of 31 bp was observed from nucleotide position 828 through 858 (or altematively positions 829 through 859; 830 through 860) inclusive (Fig 1B) . To confirm this mutation, exon 8 sequence analysis from PCR amplified genomic DNA was performed. In three of six subclones of FTR products the same deletion was observed. This approach was also used to confirm the deletion in the proband's brother and was observed in four of six subclones. The deletion was excluded in the proband's sister through nucleotide sequence determination of the entire PCR amplified (nonsubcloned) exon 8. Electrophoresis of PCR products (predicted size 485 bp) in an 8% acrylamide gel showed four bands greater than or equal to 460 bp in
Family 2 (CJ).
size, in the proband, the proband's brother and the proband's daughter (Fig 2A: lanes 2, 3, and 4 , respectively). This compared with one band in the normal control (lane 1). The PCR products smaller than 460 bp (Fig 2A: lanes 4 and 5) were interpreted as the result of mispriming: none of these smaller bands hybridized with either the radiolabeled UROD cDNA or the oligonucleotide 8DEL. Figure 2B shows that all bands greater than or equal to 460 bp hybridized positively with radiolabeled UROD cDNA. Two of these four bands ( Fig  2C: lanes 2, 3, and 4 ) also hybridized with radiolabeled 8DEL, indicating that they lacked 31 bp of exon 8. Therefore, acrylamide gel electrophoresis served as a useful technique to distinguish carriers from noncarriers for this UROD mutation. The autoradiographs suggested that the smallest band at about 460 bp represented the abnormal PCR product that harbored the 31 bp deletion. This was confirmed on nucleotide sequence analysis. The higher bands (Fig 2A, B , and C: lanes 2 to 4, of approximately 950 bp) were attributed to homoduplexes andor heteroduplexes of the PCR products.
The 31-bp deletion observed in this family was predicted to cause a frameshift and the premature introduction of a stop codon 19 amino acids downstream (Table 4) : the predicted protein would therefore be truncated and of 288 amino acids in length including 18 anomalous amino acid residues.
In the proband of family 3 (MB), the nucleotide sequence of exons was characterized by sequencing clones derived from both cDNA and genomic DNA (exons 5, 6, 7, and 9). Nucleotide sequencing revealed a C deletion at nucleotide position 890, (or alternative positions 891 and 892) which predicted loss of an Sma I site in the cDNA. In addition, there was a T to A substitution at nucleotide position 776 of the UROD coding region on the same allele (Fig 1C) . Both these changes were confirmed in the proband's daughter in two of four full-length cDNA clones. In addition, the predicted loss of the Sma I site was docu-
Family 3 (MB).
For personal use only. on November 11, 2017. by guest www.bloodjournal.org From mented by failure of the restriction endonuclease Sma I to cleave a clone derived from PCR amplified cDNA from this family (data not shown). As a result of the deletion there was a shift in the reading frame and the introduction of a premature stop codon 8 amino acids downstream ( Table 4) . This resulted in a predicted UROD protein of 291 amino acids plus 7 anomalous amino acid residues. The nucleotide substitution at position 776 resulted in glutamine replacing leucine at amino acid position 253 within the truncated protein ( Table 4) . In the proband of family 4 (MR), six clones from both halves of the UROD cDNA were characterized. In 4 of 6 clones from the 3' half of the cDNA, a G to A point mutation at nucleotide position 970 was observed (Fig 1D) which predicts an amino acid change from glycine to arginine at position 318 ( Table 4) . To confirm this abnormality, the region of exon 10 that encompassed the putative mutation was also characterized from genomic DNA. Genomic DNA from both the proband and the proband's parents
Family 4 (MR).
was analyzed. In the proband, four of six clones and in the proband's father, four of five clones confirmed the point mutation: the remaining clones represented the normal allele. All six clones from the proband's mother were normal with no evidence of the mutation.
In family 5 (AI), nucleotide sequencing of four full-length cDNA clones revealed a C to G point mutation in exon 4 at nucleotide position 257 (Fig lE) , which predicted the substitution of alanine to glycine at amino acid position 80 ( Table 4) . This mutation was confirmed by analysis of genomic DNA: PCR amplification of exon 4 revealed the same abnormality. Consistent with the more severe clinical symptoms observed in this patient, sequence analysis of the entire PCR product revealed a guanine residue alone at nucleotide position 257. This suggested that the patient was homozygous for this abnormality. Cloning and sequencing of exon 4 (amplified from genomic DNA) in the proband's father and brother identified both the normal C and the mutant G nucleotides (Fig 1E) indicating a heterozygous state. 
Family 5 (AI).
Variations From the Published UROD cDNA Sequence
In addition to the mutations described above, four single nucleotide changes at positions 87, 325, 931, and 1027, and a triple base change, GCG to CGC at nucleotide position 376 to 378, were observed. The latter change predicts an arginine (instead of alanine), at amino acid position 120. The differences from the published UROD sequence were seen in all sequences characterized and have been described previou~Iy.'~~~'~-'-'
Expression of Mutant UROD Proteins in Vitro
Experiments were performed to examine the functional activity of in vitro translated UROD proteins. To synthesize full-length UROD cDNA, cross-over PCR was performed to generate constructs for each mutation and with confirmation by nucleotide sequence determination. The pMAL-p2 vector was used to generate the UROD protein fused to maltose binding protein (MBP) with a four amino acid intervening sequence that could be recognized and cleaved by factor Xa. The fusion proteins generated were partially purified by passage through an amylose column before factor Xa cleavage. Westem analysis was performed on the fusion and cleaved proteins (Fig 3) (Fig 3B) . AS expected, both mutations that resulted in a frameshift and premature termination yielded truncated fusion proteins (about 64 kD in size). This was true for the 31 bp deletion in exon 8 (family 2 [CJ] ) and the C deletion in exon 8 (family 3 [MB]) (data not shown). Neither of these fusion proteins could be cleaved by factor Xa. This suggested that the conformation of these truncated fusion proteins was such that the factor Xa recognition site was inaccessible to factor Xa (Fig 3A) . In addition, when analyzed by Westem blotting these proteins were detected by reaction with the anti-UROD antisera (Fig 3A) but not the anti-MBP antisera (Fig 3B) . Thus, even in denaturing conditions, MBP epitopes were not recognized by anti-MBP antisera.
Although the majority of fusion proteins were able to be partially purified, attempts to partially purify one of the in vitro generated mutant proteins (family 1 [KD]), was unsuccessful: no protein was detected by Westem analysis as either a fusion protein or as the cleaved UROD protein. It was reasoned that perhaps this mutation, isoleucine to threonine at amino acid position 334 rendered the protein relatively insoluble in the bacterial expression system used here. To test this hypothesis, Western analysis was performed on the supernatant and the cell debris suspension from crude bacterial extracts. Using the anti-MBP antisera, a fusion protein of about 80 kD was detected for the normal control and family 1 (KD), (data not shown). Although the anti-UROD antisera failed to detect the fusion protein, possibly because of lack of sensitivity, UROD activity was detected: supernatants were cleaved with factor Xa and UROD activity determined.
Activity of Expressed Mutant Proteins
The UROD activity of the in vitro generated mutant proteins was determined using pentacarboxylic acid porphyrinogen I as the substrate. UROD activities were expressed as a percentage of the normal UROD protein and the results are shown in Table 4 . UROD activity was also measured using partially purified proteins or crude bacterial extracts derived from the pMAL-p2 vector alone and found to be negligible. In control experiments, up to a twofold variation was observed between batches of the in vitro produced normal UROD protein. However, within a batch, the uncleaved normal UROD protein had an activity identical to the cleaved protein (data not shown). The variation between batches was taken into consideration when determining the activity of mutant proteins relative to the activity of the normal UROD protein.
The level of UROD activity observed with the mutant proteins was variable and depended on the type and site of mutation ( Table 4) . Thus for example, the full-length UROD proteins from family 1 (KD) and from family 5 (AI), had some residual catalytic activity when compared with the normal UROD protein. This compared with family 2 (CJ). where no activity was detected. In contrast, the activity of another of the expressed proteins (family 4 [MR] ) was approximately 100% of normal.
Stability of the In Vitro Translated UROD Protein Derived From Family 4 (MR)
These studies showed that the stability of the in vitro translated UROD protein derived from family 4 (MR) was not significantly different from the normal UROD protein (Fig 4) in the presence of a normal lymphocyte lysate.
DISCUSSION
In this report we describe five new mutations in the UROD gene in families with cutaneous porphyria. These mutations were documented in the proband and at least one relative. The in vitro expression of UROD protein showed that the activity of these mutant proteins was substantially perturbed with the exception of the UROD protein derived from family
(MR).
Although several mutations have been described in the UROD gene to account for HEP, only two have been described in fPCT (see Table 5 ). The six new mutations in the UROD coding region described here occurred in five unrelated families. None of these mutations were detected by nucleotide sequence analysis in three other unrelated individuals that we examined with low erythrocyte UROD activity and diagnosed with fPCT (data not shown).
Garey et a12' described a mutation in the splice junction of exon 6 present in 5 of 22 apparently unrelated families with fPCT and suggested that this mutation was a common cause of fPCT. However, we did not detect this mutation in any of the eight aforementioned families. In addition, Elder et a134 failed to detect this mutation in 25 European patients with fPCT. This suggests that the families studied by Garey et al" may have demonstrated an unsuspected "founder effect."
The C to G mutation in family 5 (AI), diagnosed with HEP, was detected in all four clones sequenced in the proband and also evidenced in the homozygous state by sequencing of the entire PCR product without prior cloning. Although it is conceivable that the PCR technique preferentially amplified one allele, this seems very unlikely for several reasons. Firstly, the erythrocyte UROD activity was markedly decreased (12% of normal), secondly the erythrocyte protoporphyrin levels were elevated, thirdly, the proband was born of a consanguinous marriage and finally, cloning and sequencing of exon 4 amplified from the brother and father revealed both C and G nucleotides at position 257. Therefore, it seems very likely that the proband was homozygous for the alanine to glycine substitution at amino acid position 80. CpG dinucleotides are well known to be sites particularly susceptible to mutation. A collation of single base mutations in human disease showed that 35% of these mutations occurred at CpG dinucleotides. Of these, 90% were C to T, or G to A substitution^.^^ The most common DNA modification in eukaryotes is methylation of cytosine which occurs most often within CpG dinucleotides and 5-methylcytosine has a propensity to deaminate to form t h~m i d i n e .~~.~' It is also suggested that methylation within coding regions may contribute significantly to the incidence of genetic disease in humans. 35 The point mutation we described in family 4 (MR) occurred at a CpG site (969/970): ATC/GGG to ATC/AGG and the commonly observed G to A substitution was noted.
Two of the mutations reported here involved deletions and the local DNA sequence is probably important in their origin.3x The occurrence of deletions is not a random process. For example direct repeat sequences have been found in the region of most deletions. They feature in certain replication, recombination or repair models of mutation by d e l e t i~n .~~ A consensus sequence involved in human gene deletions has been determined. A sequence that complies with this consensus was located in the vicinity of the 31-bp deletion in exon 8 of family 2 (CJ). This sequence is thought to act as an arrest site for human polymerase a during replication. It has been proposed that dissociation of polymerase a at arrest sites may lead to deletion by slipped mispairing due to a change in secondary structure3' or switching to the other strand4' or incorporating the incorrect base. 4' In this study, mutations were observed in four exons, with exons 8 and 10 having two mutations each. It has already been established that exon 8 is probably important for the normal function of the UROD protein. For example, two point mutations have previously been described in exon 8 (nucleotide position 860) that change the glycine at amino acid position 281 to either valine in fPCT2' or glutamate in HEP." Both mutations yielded proteins that were rapidly degraded. de Verneuil et a12' described another point mutation in exon 8 (nucleotide position 892) and suggested that the arginine residue at amino acid position 292 might be critical for the binding of acetate or propionate side chains of uroporphyrinogen at the active site.
This report brings to 5 the number of examples where mutations have occurred in exon 8. Thus, exon 8 appears to be a frequent target for mutations of the missense and deletion type. This may be a result of either the specific nucleotide sequence or may reflect the relative functional importance of this part of the UROD protein.
In family 4 (MR), the UROD activity in the mutant protein was approximately loo%, suggesting that the glycine to arginine change at amino acid position 3 18 had little or no impact on the enzyme function. This is despite the difference in size of the arginine residue that replaced glycine. Others have also noted mutations in the UROD gene that were associated with protein function in the vicinity of normal." The possibility that the glycine to arginine substitution affected the decarboxylation of one of the other three UROD substrates ie, uroporphyrinogen, 7 carboxylic acid porphyrinogen or 6 carboxylic acid porphyrinogen was considered. However, preliminary studies with uroporphyrinogen 111 as substrate, suggested that this amino acid substitution had no effect on decarboxylation of uroporphyrinogen I11 to coproporphyrinogen 111. Then the possibility that this protein might display reduced stability was investigated. This notion is supported by the results of immune quantitation of UROD in this family: the levels of immunoreactive UROD were decreased proportionally to the decrease in protein activity observed in the patient. However, the results of this study revealed that the mutant was as stable as the normal UROD protein.
The possibility remains that the in vitro system used to measure the stability does not adequately reflect the in vivo situation and that the protein is unstable in vivo. It was intriguing to note that each of the amino acids that were the targets of point mutation in this study are conserved in at least one other species ( Table 6) . The isoleucine at amino acid position 334 is most highly conserved as shown by its presence at an equivalent position in rat, yeast, Bacillus subtilis and Synechococcus sp strain PCC7942. The leucine residue at amino acid position 253 was also conserved in rat and Synechococcus sp strain PCC7942. However, we did not specifically determine how the leucine to glutamine substitution impacted on UROD function. Interestingly, in the amino acid position equivalent to 318 (where a glycine is found in the human gene), the substituted arginine residue occurs naturally in Synechococcus sp strain PCC7942 ( Table  6 ). This could explain the normal or near normal function observed in the expressed UROD protein from family 4 (MR). It was also apparent that the alanine at amino acid position 80 was highly conserved, although a glycine (the substituted amino acid seen in family 5 [AI]) was found at the equivalent position in Synechococcus sp strain PCC7942. This could account for the residual activity of this mutant UROD protein in the HEP patient observed in vivo.
In summary, the five new mutations in the UROD gene presented here provide evidence to suggest that the genetic causes of fPCT are heterogeneous and support genetic heterogeneity in the cause of HEP. In addition, the identification of these mutations also serves to highlight areas of the UROD protein that may be structurally significant and vulnerable to mutation.
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NOTE ADDED IN PROOF
Around the time of submission of this manuscript, it was noted that another mutation in the UROD gene had been described in fPCT. Roberts AG, Elder GH, De Salamanca RE, Herrero C, Lecha M, Mascaro JM: A mutation (G281E) of the human uroporphyrinogen decarboxylase gene causes both hepatoerythropoietic porphyria and overt familial porphyria cutanea tarda: Biochemical and genetic studies on Spanish patients. J Invest Dermatol 104:500, 1995.
